164 related articles for article (PubMed ID: 27392838)
1. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases.
Horii A; Uno A; Kitahara T; Mitani K; Masumura C; Kizawa K; Kubo T
J Vestib Res; 2007; 17(1):1-8. PubMed ID: 18219099
[TBL] [Abstract][Full Text] [Related]
3. Milnacipran and selective serotonin reuptake inhibitors in major depression.
Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
[TBL] [Abstract][Full Text] [Related]
4. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness.
Horii A; Mitani K; Kitahara T; Uno A; Takeda N; Kubo T
Otol Neurotol; 2004 Jul; 25(4):536-43. PubMed ID: 15241233
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
Morishita S; Arita S
Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
[TBL] [Abstract][Full Text] [Related]
6. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
Fukuchi T; Kanemoto K
Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
[TBL] [Abstract][Full Text] [Related]
8. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
Morishita S; Arita S
Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
[No Abstract] [Full Text] [Related]
10. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
Higuchi H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
Clerc G;
Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease.
Mizukami K; Hatanaka K; Tanaka Y; Sato S; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):349-52. PubMed ID: 19166899
[TBL] [Abstract][Full Text] [Related]
13. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.
Puech A; Montgomery SA; Prost JF; Solles A; Briley M
Int Clin Psychopharmacol; 1997 Mar; 12(2):99-108. PubMed ID: 9219045
[TBL] [Abstract][Full Text] [Related]
14. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
Kasper S; Pletan Y; Solles A; Tournoux A
Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
[TBL] [Abstract][Full Text] [Related]
15. Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.
Yoshimura R; Mitoma M; Sugita A; Hori H; Okamoto T; Umene W; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1034-7. PubMed ID: 17459550
[TBL] [Abstract][Full Text] [Related]
16. Anxiety disorders and other psychiatric subgroups in patients complaining of dizziness.
Eckhardt-Henn A; Breuer P; Thomalske C; Hoffmann SO; Hopf HC
J Anxiety Disord; 2003; 17(4):369-88. PubMed ID: 12826087
[TBL] [Abstract][Full Text] [Related]
17. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease.
Mizukami K; Tanaka Y; Asada T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1342-6. PubMed ID: 16603301
[TBL] [Abstract][Full Text] [Related]
19. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
